GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Metrics to compare | GLYC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGLYCPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.4x | −1.8x | −0.6x | |
PEG Ratio | −0.21 | −0.03 | 0.00 | |
Price/Book | 1.5x | −0.4x | 2.6x | |
Price / LTM Sales | 1,657.2x | 57.6x | 3.1x | |
Upside (Analyst Target) | 278.8% | 116.2% | 51.5% | |
Fair Value Upside | Unlock | 20.3% | 7.6% | Unlock |